Evidence map›Paper›PMID 32821415›Full record

ArticleCanadian journal of kidney health and disease2020

Canadian Society of Nephrology Commentary on the Kidney Disease Improving Global Outcomes 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder.

Rachel M Holden, Reem A Mustafa, R Todd Alexander, Marisa Battistella, Micheli U Bevilacqua, Greg Knoll, Fabrice Mac-Way, Martina Reslerova, Ron Wald, Philip D Acott and 14 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Canadian journal of kidney health and disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Inhibit progression of coronary artery calcification with vitamin K in hemodialysis patients (the iPACK-HD study): a randomized, placebo-controlled multi-center, pilot trial.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023
    Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 18 institutions in 2 countries.

Rachel M HoldenDivision of Nephrology, Department of Medicine, Queen's University, Kingston, ON, Canada.ORCID https://orcid.org/0000-0001-6431-3127
Reem A MustafaDivision of Nephrology and Hypertension, Department of Internal Medicine, The University of Kansas Medical Center, Kansas City, USA.
R Todd AlexanderDepartment of Pediatrics and Physiology, University of Alberta, Edmonton, Canada.
Marisa BattistellaUniversity Health Network, Leslie Dan Faculty of Pharmacy, University of Toronto, ON, Canada.
Micheli U BevilacquaDivision of Nephrology, Department of Medicine, The University of British Columbia, Vancouver, Canada.
Greg KnollDivision of Nephrology, The Ottawa Hospital, ON, Canada.
Fabrice Mac-WayDivision of Nephrology, CHU de Québec, Hôtel-Dieu de Québec Hospital, Université Laval, Québec City, QC, Canada.
Martina ReslerovaNephrology Section, St. Boniface General Hospital, University of Manitoba, Winnipeg, Canada.
Ron WaldDivision of Nephrology, St. Michael's Hospital, University of Toronto, ON, Canada.ORCID https://orcid.org/0000-0003-4411-8169
Philip D AcottDivision of Nephrology, Department of Pediatrics, Dalhousie University, Halifax, NS, Canada.
Patrick FeltmateDepartment of Geriatric Medicine, Dalhousie University, Halifax, NS, Canada.
Allan GrillDepartment of Family & Community Medicine, University of Toronto, ON, Canada.
Kailash K JindalDivision of Nephrology, Department of Medicine, University of Alberta, Edmonton, Canada.
Meena KarsanjiProfessional Practice, Vancouver Coastal Health, Richmond, BC, Canada.
Bryce A KiberdDivision of Nephrology, Department of Medicine, Dalhousie University, Halifax, NS, Canada.
Sara MahdaviDepartment of Nutritional Sciences, University of Toronto, ON, Canada.
Kailee McCarronNova Scotia Renal Program, Nova Scotia Health Authority, Halifax, Canada.
Amber O MolnarDivision of Nephrology, McMaster University, Hamilton, ON, Canada.ORCID https://orcid.org/0000-0003-4549-0202
Maury PinskDivision of Nephrology, Department of Pediatrics & Child Health, University of Manitoba, Winnipeg, Canada.
Celia RoddDivision of Diabetes & Endocrinology, Department of Pediatrics & Child Health, University of Manitoba, Winnipeg, Canada.
Steven D SorokaDivision of Nephrology, Department of Medicine, Dalhousie University, NSHA Renal Program and Pharmacy Services, Halifax, NS, Canada.ORCID https://orcid.org/0000-0002-7278-1702
Amanda J VinsonDivision of Nephrology, Dalhousie University, Halifax, NS, Canada.
Deborah ZimmermanDivision of Nephrology, Department of Medicine, University of Ottawa, ON, Canada.
Catherine M ClaseDivision of Nephrology, Department of Medicine, Department of Health Research, Evidence and Impact, McMaster University, Hamilton, ON, Canada.ORCID https://orcid.org/0000-0002-4538-5958
Dalhousie University · CAUniversity of Alberta · CAUniversity of Toronto · CAHealth Sciences Centre · CAHôtel-Dieu de Québec · CAImpact · CAManitoba Health · CAMcMaster University · CANova Scotia Health Authority · CAOttawa Hospital · CAQueen's University · CASt. Boniface Hospital · CASt. Michael's Hospital · CAUniversity Health Network · CAUniversity of British Columbia · CAUniversity of Kansas Medical Center · USUniversity of Ottawa · CAVancouver Coastal Health · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of review(1) To provide commentary on the 2017 update to the Kidney Disease Improving Global Outcomes (KDIGO) 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD); (2) to apply the evidence-based guideline update for implementation within the Canadian health care system; (3) to provide comment on the care of children with chronic kidney disease (CKD); and (4) to identify research priorities for Canadian patients. SOURCES OF INFORMATION: The KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of CKD-MBD.

methodsThe commentary committee co-chairs selected potential members based on their knowledge of the Canadian kidney community, aiming for wide representation from relevant disciplines, academic and community centers, and different geographical regions. KEY

findingsWe agreed with many of the recommendations in the clinical practice guideline on the diagnosis, evaluation, prevention, and treatment of CKD-MBD. However, based on the uncommon occurrence of abnormalities in calcium and phosphate and the low likelihood of severe abnormalities in parathyroid hormone (PTH), we recommend against screening and monitoring levels of calcium, phosphate, PTH, and alkaline phosphatase in adults with CKD G3. We suggest and recommend monitoring these parameters in adults with CKD G4 and G5, respectively. In children, we agree that monitoring for CKD-MBD should begin in CKD G2, but we suggest measuring ionized calcium, rather than total calcium or calcium adjusted for albumin. With regard to vitamin D, we suggest against routine screening for vitamin D deficiency in adults with CKD G3-G5 and G1T-G5T and suggest following population health recommendations for adequate vitamin D intake. We recommend that the measurement and management of bone mineral density (BMD) be according to general population guidelines in CKD G3 and G3T, but we suggest against routine BMD testing in CKD G4-G5, CKD G4T-5T, and in children with CKD. Based on insufficient data, we also recommend against routine bone biopsy in clinical practice for adults with CKD or CKD-T, or in children with CKD, although we consider it an important research tool. LIMITATIONS: The committee relied on the evidence summaries produced by KDIGO. The CSN committee did not replicate or update the systematic reviews.

Indexed as

CanadaCKD (chronic kidney disease)guidelinesKDIGOmineral bone disease

Identifiers

PMID32821415
PMCPMC7412914
OpenAlexW3047309139

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.